Medincell SA
PAR:MEDCL
Medincell SA
Revenue
Medincell SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medincell SA
PAR:MEDCL
|
Revenue
€10.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Revenue
€44.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-2%
|
|
|
Ipsen SA
PAR:IPN
|
Revenue
€3.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Vetoquinol SA
PAR:VETO
|
Revenue
€537.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Virbac SA
PAR:VIRP
|
Revenue
€1.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Boiron SA
PAR:BOI
|
Revenue
€481.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
Medincell SA
Glance View
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
See Also
What is Medincell SA's Revenue?
Revenue
10.7m
EUR
Based on the financial report for Sep 30, 2024, Medincell SA's Revenue amounts to 10.7m EUR.
What is Medincell SA's Revenue growth rate?
Revenue CAGR 5Y
32%
Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Medincell SA have been 8% over the past three years , 32% over the past five years .
You don't have any saved screeners yet